Das Team von Walder Wyss wurde von Alex Nikitine (Partner, Corporate/M&A) geleitet und umfasste Thiemo Sturny (Partner, Corporate/M&A), Dimitrios Berger (Associate, Corporate/M&A), Hugh Reeves (Senior Associate, IP/IT) und Judith Rothen (Trainee,
Memo Therapeutics äussert sich wie folgt zur Transaktion:
«Memo Therapeutics AG, an innovator in the field of antibody discovery and immune repertoire analysis, announced today that the company has raised CHF 14 million in Series B financing. The round was led by Swisscanto Invest by Zürcher Kantonalbank and included BERNINA BioInvest, as well as new private investors and existing investors Investiere, Schroder Adveq, Jaquet Partners, and Redalpine.»
Der CEO der Memo Therapeutics AG, Dr. Karsten Fischer, gibt folgendes Statement ab: “We are thrilled that with Swisscanto Invest and Bernina BioInvest we could attract two new renowned investors into our existing syndicate to support the clinical development of our two antiviral assets. We see this as validation of our antibody discovery approach and the huge future potential for the company,” said Dr. Karsten Fischer, CEO of Memo Therapeutics AG.»
CEO Dr. Karsten Fischer CV
Dr. Karsten Fischer is Memo Therapeutics AG CEO and a senior executive in the life science field. Prior to joining Memo Therapeutics AG, he was a partner of BioMedPartners AG, a renowned European Venture Capitalist in the field of biotechnology, medical technology and diagnostics, where he did several investments into successful companies. Previously, Dr. Fischer has been working for WestLB in the healthcare and chemicals sector where he was heading the equity capital markets team realizing large primary market transactions and the strategic analysis working on debt, M&A, and equity transactions. He started his career with Deutsche Venture Capital, an affiliate of Deutsche Bank, investing into bio- and medical technology companies. He then consulted large cap pharmaceutical companies with McKinsey&Company on sales and marketing strategies before he went to Sanofi Aventis being responsible for Sales Force and Marketing Excellence. He has a biochemistry and economics background and holds a Ph.D. in infection biology (MPI Infection Biology and Colorado State University, with distinction).
